PURPOSE:
This study by Roberge et al. (AJOG, 2017) surveyed previously performed randomized control trials (RCTs) to determine at what point during pregnancy aspirin should be introduced to reduce the risk of preeclampsia.
METHODS:
Systematic Review and Meta-Analysis
RESULTS:
This study analyzed 45 studies which included 20,909 women. Women received aspirin or a placebo starting at ≤ 16 weeks or > 16 weeks. Women who began taking aspirin ≤ 16 weeks displayed lower risk or preeclampsia and fetal growth restriction than those who began taking aspirin > 16 weeks. They also found that the greater the dose, the greater the decrease in risk.